CAJ | 학술논문

　　目的探讨参麦注射液辅助支气管动脉介入治疗中晚期肺癌的临床疗效及安全性。方法将82例中晚期肺癌患者分为观察组(53例)和对照组(29例)，对照组予支气管动脉介入治疗，观察组在此基础上加用参麦注射液辅助治疗，观察两组患者治疗疗效及毒副反应情况。结果观察组治疗有效率71.69%，明显高于对照组的55.17%(P <0.05)；观察组出现恶心呕吐及白细胞减少病例明显低于对照组(P <0.05)，1年生存率、2年生存率均明显高于对照组(P <0.05)。结论在支气管动脉介入治疗基础上加用参麦注射液辅助治疗中晚期肺癌，可有效提高疗效，减少毒副反应。
　　목적탐토삼맥주사액보조지기관동맥개입치료중만기폐암적림상료효급안전성。방법장82례중만기폐암환자분위관찰조(53례)화대조조(29례)，대조조여지기관동맥개입치료，관찰조재차기출상가용삼맥주사액보조치료，관찰량조환자치료료효급독부반응정황。결과관찰조치료유효솔71.69%，명현고우대조조적55.17%(P <0.05)；관찰조출현악심구토급백세포감소병례명현저우대조조(P <0.05)，1년생존솔、2년생존솔균명현고우대조조(P <0.05)。결론재지기관동맥개입치료기출상가용삼맥주사액보조치료중만기폐암，가유효제고료효，감소독부반응。
Objective To investigate the clinical efficacy and safety of Shenmai Injection and bronchus artery intervention therapy on the treatment of metaphase or terminal lung cancer. Methods 82 cases of metaphase or terminal lung cancer were divided into the observation group(with 53 cases) and the control group(with 29 cases). The control group was treated with bronchus artery intervention therapy, while the observation group was additionally treated Shenmai Injection. Observations were carried out about the clinical efficacy and toxic and side effects of both groups. Results The effective treatment rate of the observation group was 71.69%, significantly higher than 55.17% of the control group(P <0.05). The cases in the observation group with nausea and vomiting as well as leucopenia were fewer than those in the control group(P <0.05). The one-year rate of survivors and two-year rate of survivors of the observation group were significantly higher than those of the control group(P <0.05). Conclusion With the qualities of effectively improving clinical efficacy and reducing toxic and side effects, Shenmai.